Alvotech ALVO

$4.55 +0.18 (4.12%)

Valuation

Market cap
1,318,892,000
Revenue TTM
$586,320,000
Net income TTM
$27,920,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
4.76%
Debt to equity
-5.22

Trading

Volume
1,561,400
Avg volume
1,160,808
Day's range
$4.34 – $4.67
Shares out
301,806,000
Stochastic %K
47%
Beta
0.24
Analysts
Moderate Buy
Price target
$7.50

Price

Company profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis,...

Show more

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Website
https://www.alvotech.com
Address
9, Rue de Bitbourg, Luxembourg, Luxembourg

Latest news

Stocktwits

RunnerSignals Nov 16, 8:59 PM
Market Warriros $URGN $PLBY $ALVO $ULCC $POWL all flipped green next session puts those reversals to the test
0 replies
Kosmokrat Nov 16, 4:06 PM
$ALVO I think everybody is expecting FDA approval for AVT03, AVT05 and AVT06 early December. I am pretty sure that will lift the SP above $5 again. But only the AVT06 Launch in Q4 is secured, Alvotech is still in litigation for AVT03 and AVT05. Once the FDA approvals comes in, the pressure on Amgen (AVT03) and Jannsen will be huge to come to a settlement quickly. There is already a court hearing set for April between Amgen and Alvotech, but usually Amgen would try to settle before that date. Anyopinion on when the launches for AVT03 and AVT05 will actually happen?
0 replies
LoneLegend Nov 15, 7:22 PM
$ALVO how were the earnings here?
0 replies
EarningsInsider Nov 12, 2:16 PM
https://www.marketbeat.com/earnings/reports/2026-11-11-alvotech-stock/ $ALVO Alvotech Earnings Transcript
0 replies
Kosmokrat Nov 12, 2:07 PM
$ALVO The Q3 earnings were okay, not great, but most important, Alvotech kept their guidance for 2026, even though they will come in at the lower end of the guidance. My personal question was, does that guidance already include milestone payments for the 3 FDA approvals that we all expect before year end? I am glad one analyst asked exactly that question in the call today, and the answer was, they are still confident to reach the lower end of the guidance, even if the approvals slip into next year. Also they confirmed that they will be cash flow positive in Q4, so hopefully they will not need any capital injection any more. Even though some quarters in 2027 might still be slightly cash flow negative, I do expect that 2027 in total should be cash flow positive.
1 replies
hofno2003 Nov 12, 10:04 AM
$ALVO Extrapolating Alvotech's 2026 projected revenue into 2027 yields $832.1 million using its annual growth trajectory, which aligns closely with the Wall Street consensus estimate of $785.9 million, easily justifying a PPS of $10+ due to the further accelerating growth story.
0 replies
hofno2003 Nov 12, 9:37 AM
$ALVO Alvotech's implied fourth-quarter revenue is well beyond $300 million, projecting between $326.6 million and $376.6 million to meet its full-year 2026 guidance. The most realistic implied target for Q4 sits near $326.6 million at the lower end - however it will be a blowout quarter.
0 replies
StocktwitsEarnings Nov 12, 3:08 AM
$ALVO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.24 down -700.00% YoY • Reported revenue of $111.6M down -2.02% YoY • Alvotech maintains full-year 2026 guidance for total revenue of $650M and EBITDA of $180M, with performance now expected toward the lower end of the range.
0 replies